Patents by Inventor L. David Williams
L. David Williams has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180223263Abstract: A naturally occurring or recombinant protein, especially a mutein of porcine urate oxidase (uricase), that is essentially free of large aggregates can be rendered substantially non-immunogenic by conjugation with a sufficiently small number of strands of polymer such that the bioactivity of the protein is essentially retained in the conjugate. Such conjugates are unusually well suited for treatment of chronic conditions because they are less likely to induce the formation of antibodies and/or accelerated clearance than are similar conjugates prepared from protein preparations containing traces of large aggregates.Type: ApplicationFiled: August 17, 2017Publication date: August 9, 2018Applicants: HORIZON PHARMA RHEUMATOLOGY LLC, DUKE UNIVERSITYInventors: Merry R. Sherman, Mark G. P Saifer, L. David Williams, Michael S. Hershfield, Susan J. Kelly
-
Patent number: 9885024Abstract: A naturally occurring or recombinant urate oxidase (uricase) covalently coupled to poly(ethylene glycol) or poly(ethylene oxide) (both referred to as PEG), wherein an average of 2 to 10 strands of PEG are conjugated to each uricase subunit and the PEG has an average molecular weight between about 5 kDa and 100 kDa. The resulting PEG-uricase conjugates are substantially non-immunogenic and retain at least 75% of the uricolytic activity of the unmodified enzyme.Type: GrantFiled: July 22, 2015Date of Patent: February 6, 2018Assignees: DUKE UNIVERSITY, HORIZON PHARMA RHEUMATOLOGY LLCInventors: L. David Williams, Michael S. Hershfield, Susan J. Kelly, Mark G. P. Saifer, Merry R. Sherman
-
Publication number: 20170189544Abstract: Methods are provided for the preparation of conjugates of a variety of bioactive components, especially proteins, with water-soluble polymers (e.g., poly(ethylene glycol) and derivatives thereof), which conjugates have reduced antigenicity and immunogenicity compared to similar conjugates prepared using poly(ethylene glycol) containing a methoxyl or another alkoxyl group. The invention also provides conjugates prepared by such methods, compositions comprising such conjugates, kits containing such conjugates or compositions and methods of use of the conjugates and compositions in diagnostic and therapeutic protocols.Type: ApplicationFiled: December 22, 2016Publication date: July 6, 2017Inventors: Alexa L. MARTINEZ, Merry R. SHERMAN, Mark G.P. SAIFER, L. David WILLIAMS
-
Publication number: 20160160188Abstract: A naturally occurring or recombinant urate oxidase (uricase) covalently coupled to poly(ethylene glycol) or poly(ethylene oxide) (both referred to as PEG), wherein an average of 2 to 10 strands of PEG are conjugated to each uricase subunit and the PEG has an average molecular weight between about 5 kDa and 100 kDa. The resulting PEG-uricase conjugates are substantially non-immunogenic and retain at least 75% of the uricolytic activity of the unmodified enzyme.Type: ApplicationFiled: July 22, 2015Publication date: June 9, 2016Applicants: Duke University, Crealta Pharmaceuticals LLCInventors: L. David WILLIAMS, Michael S. Hershfield, Susan J. Kelly, Mark G.P. Saifer, Merry R. Sherman
-
Patent number: 9125880Abstract: Methods are provided for the synthesis of polymer conjugates of cytokines and receptor-binding antagonists thereof, especially a non-glycosylated interferon-beta, which conjugates retain unusually high biological potency. Preparation of polymer conjugates according to the methods of the present invention diminishes or avoids steric inhibition of receptor-ligand interactions that commonly results from the attachment of polymers to receptor-binding regions of cytokines, as well as to agonistic and antagonistic analogs thereof. The invention also provides conjugates and compositions produced by such methods. The conjugates of the present invention retain a high level of biological potency compared to those produced by traditional polymer coupling methods that are not targeted to avoid receptor-binding domains of cytokines.Type: GrantFiled: December 23, 2003Date of Patent: September 8, 2015Assignee: Mountain View Pharmaceuticals, Inc.Inventors: Mark G. P. Saifer, Alexa L. Martinez, L. David Williams, Merry R. Sherman
-
Patent number: 8921064Abstract: A naturally occurring or recombinant protein, especially a mutein of porcine urate oxidase (uricase), that is essentially free of large aggregates can be rendered substantially non-immunogenic by conjugation with a sufficiently small number of strands of polymer such that the bioactivity of the protein is essentially retained in the conjugate. Such conjugates are unusually well suited for treatment of chronic conditions because they are less likely to induce the formation of antibodies and/or accelerated clearance than are similar conjugates prepared from protein preparations containing traces of large aggregates.Type: GrantFiled: April 13, 2011Date of Patent: December 30, 2014Assignees: Mountain View Pharmaceuticals, Inc., Duke UniversityInventors: Merry R. Sherman, Mark G. P. Saifer, L. David Williams, Michael S. Hershfield, Susan J. Kelly
-
Publication number: 20140363414Abstract: A naturally occurring or recombinant protein, especially a mutein of porcine urate oxidase (uricase), that is essentially free of large aggregates can be rendered substantially non-immunogenic by conjugation with a sufficiently small number of strands of polymer such that the bioactivity of the protein is essentially retained in the conjugate. Such conjugates are unusually well suited for treatment of chronic conditions because they are less likely to induce the formation of antibodies and/or accelerated clearance than are similar conjugates prepared from protein preparations containing traces of large aggregates.Type: ApplicationFiled: August 18, 2014Publication date: December 11, 2014Applicants: Mountain View Pharmaceuticals, Inc., Duke UniversityInventors: Merry R. SHERMAN, Mark G.P. Saifer, L. David Williams, Michael S. Hershfield, Susan J. Kelly
-
Patent number: 8618267Abstract: A naturally occurring or recombinant urate oxidase (uricase) covalently coupled to poly(ethylene glycol) or poly(ethylene oxide) (both referred to as PEG), wherein an average of 2 to 10 strands of PEG are conjugated to each uricase subunit and the PEG has an average molecular weight between about 5 kDa and 100 kDa. The resulting PEG-uricase conjugates are substantially non-immunogenic and retain at least 75% of the uricolytic activity of the unmodified enzyme.Type: GrantFiled: April 8, 2011Date of Patent: December 31, 2013Assignees: Mountain View Pharmaceuticals, Inc., Duke UniversityInventors: L. David Williams, Michael S. Hershfield, Susan J. Kelly, Mark G. P. Saifer, Merry R. Sherman
-
Publication number: 20130052677Abstract: A naturally occurring or recombinant urate oxidase (uricase) covalently coupled to poly(ethylene glycol) or poly(ethylene oxide) (both referred to as PEG), wherein an average of 2 to 10 strands of PEG are conjugated to each uricase subunit and the PEG has an average molecular weight between about 5 kDa and 100 kDa. The resulting PEG-uricase conjugates are substantially non-immunogenic and retain at least 75% of the uricolytic activity of the unmodified enzyme.Type: ApplicationFiled: April 8, 2011Publication date: February 28, 2013Inventors: L. David WILLIAMS, Michael S. Hershfield, Susan J. Kelly, Mark G.P. Saifer, Merry R. Sherman
-
Publication number: 20120149083Abstract: A naturally occurring or recombinant urate oxidase (uricase) covalently coupled to poly(ethylene glycol) or poly(ethylene oxide) (both referred to as PEG), wherein an average of 2 to 10 strands of PEG are conjugated to each uricase subunit and the PEG has an average molecular weight between about 5 kDa and 100 kDa. The resulting PEG-uricase conjugates are substantially non-immunogenic and retain at least 75% of the uricolytic activity of the unmodified enzyme.Type: ApplicationFiled: November 29, 2011Publication date: June 14, 2012Applicants: Duke University, Mountain View Pharmaceuticals, Inc.Inventors: L. David Williams, Michael S. Hershfield, Susan J. Kelly, Mark G.P. Saifer, Merry R. Sherman
-
Publication number: 20120114742Abstract: Methods are provided for the preparation of conjugates of a variety of bioactive components, especially proteins, with water-soluble polymers (e.g., poly(ethylene glycol) and derivatives thereof), which conjugates have reduced antigenicity and immunogenicity compared to similar conjugates prepared using poly(ethylene glycol) containing a methoxyl or another alkoxyl group. The invention also provides conjugates prepared by such methods, compositions comprising such conjugates, kits containing such conjugates or compositions and methods of use of the conjugates and compositions in diagnostic and therapeutic protocols.Type: ApplicationFiled: January 13, 2012Publication date: May 10, 2012Applicant: Mountain View Pharmaceuticals, Inc.Inventors: Alexa L. MARTINEZ, Merry R. Sherman, Mark G.P. Saifer, L. David Williams
-
Patent number: 8129330Abstract: Methods are provided for the preparation of conjugates of a variety of bioactive components, especially proteins, with water-soluble polymers (e.g., poly(ethylene glycol) and derivatives thereof), which conjugates have reduced antigenicity and immunogenicity compared to similar conjugates prepared using poly(ethylene glycol) containing a methoxyl or another alkoxyl group. The invention also provides conjugates prepared by such methods, compositions comprising such conjugates, kits containing such conjugates or compositions and methods of use of the conjugates and compositions in diagnostic and therapeutic protocols.Type: GrantFiled: September 25, 2003Date of Patent: March 6, 2012Assignee: Mountain View Pharmaceuticals, Inc.Inventors: Alexa L Martinez, Merry R Sherman, Mark G. P. Saifer, L. David Williams
-
Patent number: 8067553Abstract: A naturally occurring or recombinant urate oxidase (uricase) covalently coupled to poly(ethylene glycol) or poly(ethylene oxide) (both referred to as PEG), wherein an average of 2 to 10 strands of PEG are conjugated to each uricase subunit and the PEG has an average molecular weight between about 5 kDa and 100 kDa. The resulting PEG-uricase conjugates are substantially non-immunogenic and retain at least 75% of the uricolytic activity of the unmodified enzyme.Type: GrantFiled: April 28, 2010Date of Patent: November 29, 2011Assignees: Mountain View Pharmaceuticals, Inc., Duke UniversityInventors: L. David Williams, Michael S. Hershfield, Susan J. Kelly, Mark G. P. Saifer, Merry R. Sherman
-
Publication number: 20110287466Abstract: A naturally occurring or recombinant protein, especially a mutein of porcine urate oxidase (uricase), that is essentially free of large aggregates can be rendered substantially non-immunogenic by conjugation with a sufficiently small number of strands of polymer such that the bioactivity of the protein is essentially retained in the conjugate. Such conjugates are unusually well suited for treatment of chronic conditions because they are less likely to induce the formation of antibodies and/or accelerated clearance than are similar conjugates prepared from protein preparations containing traces of large aggregates.Type: ApplicationFiled: April 13, 2011Publication date: November 24, 2011Inventors: Merry R. Sherman, Mark G.P. Saifer, L. David Williams, Michael S. Hershfield, Susan J. Kelly
-
Patent number: 7927852Abstract: A naturally occurring or recombinant protein, especially a mutein of porcine urate oxidase (uricase), that is essentially free of large aggregates can be rendered substantially non-immunogenic by conjugation with a sufficiently small number of strands of polymer such that the bioactivity of the protein is essentially retained in the conjugate. Such conjugates are unusually well suited for treatment of chronic conditions because they are less likely to induce the formation of antibodies and/or accelerated clearance than are similar conjugates prepared from protein preparations containing traces of large aggregates.Type: GrantFiled: August 3, 2007Date of Patent: April 19, 2011Assignee: Mountain View Pharmaceuticals, Inc.Inventors: Merry R. Sherman, Mark G. P. Saifer, L. David Williams, Michael S. Hershfield, Susan J. Kelly
-
Patent number: 7927589Abstract: A naturally occurring or recombinant urate oxidase (uricase) covalently coupled to poly(ethylene glycol) or poly(ethylene oxide) (both referred to as PEG), wherein an average of 2 to 10 strands of PEG are conjugated to each uricase subunit and the PEG has an average molecular weight between about 5 kDa and 100 kDa. The resulting PEG-uricase conjugates are substantially non-immunogenic and retain at least 75% of the uricolytic activity of the unmodified enzyme.Type: GrantFiled: August 3, 2007Date of Patent: April 19, 2011Assignee: Mountain View Pharmaceuticals, Inc.Inventors: L. David Williams, Michael S. Hershfield, Susan J. Kelly, Mark G. P. Saifer, Merry R. Sherman
-
Publication number: 20100323422Abstract: A naturally occurring or recombinant urate oxidase (uricase) covalently coupled to poly(ethylene glycol) or poly(ethylene oxide) (both referred to as PEG), wherein an average of 2 to 10 strands of PEG are conjugated to each uricase subunit and the PEG has an average molecular weight between about 5 kDa and 100 kDa. The resulting PEG-uricase conjugates are substantially non-immunogenic and retain at least 75% of the uricolytic activity of the unmodified enzyme.Type: ApplicationFiled: April 28, 2010Publication date: December 23, 2010Inventors: L. David WILLIAMS, Michael S. Hershfield, Susan J. Kelly, Mark G. P. Saifer, Merry R. Sherman
-
Publication number: 20100323423Abstract: A naturally occurring or recombinant urate oxidase (uricase) covalently coupled to poly(ethylene glycol) or poly(ethylene oxide) (both referred to as PEG), wherein an average of 2 to 10 strands of PEG are conjugated to each uricase subunit and the PEG has an average molecular weight between about 5 kDa and 100 kDa. The resulting PEG-uricase conjugates are substantially non-immunogenic and retain at least 75% of the uricolytic activity of the unmodified enzyme.Type: ApplicationFiled: April 28, 2010Publication date: December 23, 2010Inventors: L. David WILLIAMS, Michael S. Herschfield, Susan J. Kelly, Mark G.P. Saifer, Merry R. Sherman
-
Patent number: 7723089Abstract: A naturally occurring or recombinant urate oxidase (uricase) covalently coupled to poly(ethylene glycol) or poly(ethylene oxide) (both referred to as PEG), wherein an average of 2 to 10 strands of PEG are conjugated to each uricase subunit and the PEG has an average molecular weight between about 5 kDa and 100 kDa. The resulting PEG-uricase conjugates are substantially non-immunogenic and retain at least 75% of the uricolytic activity of the unmodified enzyme.Type: GrantFiled: April 19, 2001Date of Patent: May 25, 2010Assignees: Mountain View Pharmaceuticals, Inc., Duke UniversityInventors: L. David Williams, Michael S. Hershfield, Susan J. Kelly, Mark G. P. Saifer, Merry R. Sherman
-
Patent number: 7229810Abstract: Methods are provided for the stabilization of proteinases by the covalent attachment of or admixture with water-soluble polymers. The resultant stabilized proteinases have increased stability under the harsh conditions used in industrial genomics, which permits their use in the extraction and isolation of nucleic acids and the identification of disease-related prion proteins at elevated temperatures in solutions containing chaotropic agents, such as sodium dodecyl sulfate, urea or guanidinium salts, conferring advantages for robotic applications.Type: GrantFiled: June 28, 2002Date of Patent: June 12, 2007Assignee: Mountain View Pharmaceuticals, Inc.Inventors: Merry R. Sherman, Alexa L. Martinez, Shyam S. Bhaskaran, L. David Williams, Mark G. P. Saifer, John A. French